Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.

NCT02826005 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
400
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ilex Medical